A FOX26 news interview featuring Dr. Alastair Thompson, a surgical oncologist at Baylor College of Medicine and the lead principal investigator of Perimeter Medical Imaging AI’s (TSX: PINK; OTC: PYNKF) pivotal trial on B-Series OCT with ImgAssist AI 2.0 for breast-conserving surgery, highlights the potential of optical coherence tomography (OCT) in enhancing surgical precision.
The interview introduces two groundbreaking advancements with the potential to transform patient care in the fight against breast cancer. Dr. Thompson is at the forefront of both, including the COMET trial, which has demonstrated that the quality of life for breast cancer patients with low-risk DCIS remains the same whether they undergo surgery or active monitoring, and Perimeter’s investigational wide-field OCT imaging technology—a cutting-edge AI-driven, ultra-high-resolution tool designed to refine surgical outcomes.
Dr. Thompson explains how Perimeter’s OCT imaging technology plays a critical role, “When we do a lumpectomy conserving the breast, we look at the outside of the lump we’ve removed to make sure we’ve got everything we need.”
Demonstrating visual images of Perimeter’s B-Series OCT with ImgAssist AI 2.0, he adds, “Within about ten minutes we can scan the whole outside of this lump and then have a look at the little thumb nail sketches and images that guide us if we need to take more or if we can just leave well enough alone and we’ve got everything we need.”
In November 2024, Perimeter reported positive topline results from a pivotal study designed to support the company’s planned FDA premarket approval (PMA) submission to market its next-generation B-Series with ImgAssist AI 2.0 for use during breast-conserving surgeries. The pivotal trial met its primary endpoint, achieving a statistically significant (p-value = 0.0050) reduction in patients with residual cancer during surgery. These results demonstrated super-superiority (lower bound of confidence interval for treatment effect greater than a predetermined minimal clinically meaningful difference) of the Perimeter B-Series OCT with ImgAssist AI 2.0 system’s ability to aid surgeons in achieving clear surgical margins during surgery, potentially lowering the need for reoperation.
According to Perimeter, the company plans to submit its FDA PMA for B-Series OCT with ImgAssist AI 2.0 in early 2025.
